305 related articles for article (PubMed ID: 27283030)
1. Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.
Shin J; Lee JO; Choe JY; Bang SM; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):274-278. PubMed ID: 27283030
[TBL] [Abstract][Full Text] [Related]
2. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
Foster WR; Bischin A; Dorer R; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
[TBL] [Abstract][Full Text] [Related]
3. Clinical importance of human herpes virus-8 and human immunodeficiency virus infection in primary effusion lymphoma.
Kumode T; Ohyama Y; Kawauchi M; Yamaguchi T; Miyatake J; Hoshida Y; Tatsumi Y; Matsumura I; Maeda Y
Leuk Lymphoma; 2013 Sep; 54(9):1947-52. PubMed ID: 23278643
[TBL] [Abstract][Full Text] [Related]
4. Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis.
Shah NN; Harrison N; Stonecypher M; Frank D; Amorosa V; Svoboda J
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e157-60. PubMed ID: 25027567
[No Abstract] [Full Text] [Related]
5. Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma presenting with cardiac tamponade: A case report.
Kim HJ; Lee K; Yoon CH; Bang SM
Medicine (Baltimore); 2017 Oct; 96(43):e8010. PubMed ID: 29068981
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
7. Primary effusion lymphoma.
Chen YB; Rahemtullah A; Hochberg E
Oncologist; 2007 May; 12(5):569-76. PubMed ID: 17522245
[TBL] [Abstract][Full Text] [Related]
8. [Prolonged survival in a patient with human herpesvirus-8-negative primary effusion lymphoma after combination chemotherapy with rituximab].
Suzuki K; Ino K; Sugawara Y; Mizutani M; Sekine T; Katayama N
Gan To Kagaku Ryoho; 2008 Apr; 35(4):691-4. PubMed ID: 18408447
[TBL] [Abstract][Full Text] [Related]
9. HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases.
Takahashi T; Hangaishi A; Yamamoto G; Ichikawa M; Imai Y; Kurokawa M
Am J Hematol; 2010 Jan; 85(1):85-7. PubMed ID: 20029949
[No Abstract] [Full Text] [Related]
10. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
12. Rare primary effusion lymphoma associated with HHV-8 in Japan.
Ikebe T; Amemiya Y; Saburi M; Ando T; Kohno K; Ogata M; Hiramatsu K; Kadota J
Intern Med; 2010; 49(13):1303-6. PubMed ID: 20606364
[TBL] [Abstract][Full Text] [Related]
13. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
16. EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus.
Okada K; Asakura S; Yano T; Kishimoto T
Int J Hematol; 2018 Sep; 108(3):329-334. PubMed ID: 29516290
[TBL] [Abstract][Full Text] [Related]
17. Primary Effusion Lymphoma-like Lymphoma in a Patient with Neurofibromatosis Type 1.
Oki M; Nanao T; Shinoda T; Tsuda A; Yasuda A; Seki T; Ozawa H; Nakamura N; Takagi A
Tokai J Exp Clin Med; 2016 Sep; 41(3):123-9. PubMed ID: 27628603
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
19. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
